Rezafungin

Active substance Rezafungin
Domain Infectious diseases
Reason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)
Main indication Other infectious diseases
Extended indication Patients With Candidemia and/or Invasive Candidiasis

Product

Proprietary name Biafungin
Manufacturer Cidara
Mechanism of action Enzyme inhibitor
Route of administration Intravenous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional comments Glucan synthase inhibitors

Registration

Registration route Centralised (EMA)
Submission date 2020
Expected Registration 2021
Orphan drug No
Registration phase Clinical trials
Additional comments Datum indiening en verwachte registratie op basis van estimated primary completion datum in september 2020.

Therapeutic value

Therapeutic value No judgement
Substantiation Verwacht wordt dat er zeker een plek is in de poliklinische setting.
Duration of treatment Average 3 week / weeks
Frequency of administration 1 times a week
Dosage per administration 200 mg
References NCT03667690

Expected patient volume per year

Patient volume

10 - 50

Market share is generally not included unless otherwise stated.

References Hanemaaijer et al. Ned Tijdschr Med Microbiol 2016; 24 nr. 1
Additional comments In Europa betreft de incidentie van invasieve candidiasis ongeveer 1-11 per 100.000 inwoners. Voor Nederland zou dit ongeveer 170-1.870 gevallen betreffen. De verwachting is dat enkele tientallen patiënten daadwerkelijk in aanmerking komen.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.